Cancer Therapy : Preclinical C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN 4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin

Purpose: We have previously shown that CLDN4 (encoding claudin-4), a cell tight junction (TJ) protein, is highly expressed in human epithelial ovarian carcinomas (EOC) but undetectable in normal ovaries. CLDN4 has been identified as a specific receptor for C terminus of Clostridium perfringens enterotoxin (C-CPE), a nontoxic molecule that may disrupt TJ barrier function and enhance cellular absorption. The purpose of this study was to determine the potential clinical applications of C-CPE and its effects on CLDN4 expression in EOC. Experimental Design: Using a 3-dimensional culture model and monolayer culture of EOC cells, we examined the effects of C-CPE on CLDN4 expression by quantitative real-time PCR, immunofluorescence, and Western blot. The synergistic effect of C-CPE to clinically relevant chemotherapies (Taxol and Carboplatin) was observed in EOC culture and xenograft mice. Furthermore, we determined through oligonucleotide microarray analysis that the transcript profile alterations dysregulated as a consequence of

[1]  S. Howell,et al.  Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors , 2009, Molecular Cancer Therapeutics.

[2]  R. Berkowitz,et al.  Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. , 2009, Neoplasia.

[3]  S. Sukumar,et al.  Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. , 2007, Cancer research.

[4]  Chun-Min Lo,et al.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. , 2007, Neoplasia.

[5]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[6]  M. Brännström,et al.  Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours , 2006, International journal of cancer.

[7]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[8]  H. Mizuguchi,et al.  Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[9]  P. Morin,et al.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy. , 2005, Cancer research.

[10]  J. Wolf,et al.  An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. , 2005, Gynecologic oncology.

[11]  E. Siegel,et al.  Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. , 2005, Cancer research.

[12]  H. Mizuguchi,et al.  A Novel Strategy for the Enhancement of Drug Absorption Using a Claudin Modulator , 2005, Molecular Pharmacology.

[13]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[14]  Pedram Argani,et al.  Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. , 2004, The American journal of pathology.

[15]  B. McClane,et al.  New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin. , 2004, Anaerobe.

[16]  Christine A Iacobuzio-Donahue,et al.  Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. , 2004, American journal of clinical pathology.

[17]  Kathleen R. Cho,et al.  Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Markman.  Intraperitoneal antineoplastic drug delivery: rationale and results. , 2003, The Lancet. Oncology.

[19]  E. Dees,et al.  The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer , 2002, Breast Cancer Research.

[20]  O. Cummings,et al.  Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. , 2001, Cancer research.

[21]  Zhijian Gao,et al.  Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  B. McClane,et al.  Comparative Biochemical and Immunocytochemical Studies Reveal Differences in the Effects of Clostridium perfringens Enterotoxin on Polarized CaCo-2 CellsVersus Vero Cells* , 2001, The Journal of Biological Chemistry.

[23]  J. Anderson,et al.  Molecular structure of tight junctions and their role in epithelial transport. , 2001, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[24]  Shoichiro Tsukita,et al.  Multifunctional strands in tight junctions , 2001, Nature Reviews Molecular Cell Biology.

[25]  M. Osanai,et al.  Occludin and Claudin-1 Concentrate in the Midbody of Immortalized Mouse Hepatocytes During Cell Division , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[27]  J. Lindsay,et al.  Evidence for Clostridium perfringens Enterotoxin (CPE) Inducing a Mitogenic and Cytokine Response In Vitro and a Cytokine Response In Vivo , 1999, Current Microbiology.

[28]  K. Fujimoto,et al.  Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[30]  B. McClane,et al.  Deletion analysis of the Clostridium perfringens enterotoxin , 1997, Infection and immunity.

[31]  C. Obasaju,et al.  Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  E. Karsenti,et al.  Orientation of spindle axis and distribution of plasma membrane proteins during cell division in polarized MDCKII cells , 1994, The Journal of cell biology.

[33]  D. Garrod,et al.  Epithelial cells retain junctions during mitosis. , 1993, Journal of cell science.

[34]  G. Schoolnik,et al.  Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region. , 1991, The Journal of biological chemistry.

[35]  G. Sakaguchi,et al.  Production and characterization of monoclonal antibodies to Clostridium perfringens enterotoxin , 1986, Infection and immunity.

[36]  R. Coleman.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2007 .

[37]  Zhijian Gao,et al.  p53 Tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol. , 2002, The Journal of clinical endocrinology and metabolism.

[38]  園田 紀之.  Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands : Evidence for direct involvement of claudins in tight junction barrier , 2002 .

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.